View in EDS HTML Full Text PDF Full Text

The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.

Saved in:
Bibliographic Details
Title: The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
Authors: Lübker C; Novo Nordisk A/S, Søborg, Denmark. cjlu@novonordisk.com., Bhavsar J; Novo Nordisk Inc., Plainsboro, NJ, USA., Duque do Vale R; Novo Nordisk A/S, Søborg, Denmark., Emerson SS; Department of Biostatistics, University of Washington, Seattle, WA, USA., Nørtoft E; Novo Nordisk A/S, Søborg, Denmark., Plutzky J; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA., Roberts G; Health Economics and Outcomes Research Ltd, Cardiff, UK., Tarp JM; Novo Nordisk A/S, Søborg, Denmark., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Source: Advances in therapy [Adv Ther] 2025 May; Vol. 42 (5), pp. 2513-2525. Date of Electronic Publication: 2025 Mar 29.
Publication Type: Journal Article
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40156748
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lübker+C%22">Lübker C</searchLink>; Novo Nordisk A/S, Søborg, Denmark. cjlu@novonordisk.com.<br /><searchLink fieldCode="AU" term="%22Bhavsar+J%22">Bhavsar J</searchLink>; Novo Nordisk Inc., Plainsboro, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Duque+do+Vale+R%22">Duque do Vale R</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Emerson+SS%22">Emerson SS</searchLink>; Department of Biostatistics, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Nørtoft+E%22">Nørtoft E</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Plutzky+J%22">Plutzky J</searchLink>; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Roberts+G%22">Roberts G</searchLink>; Health Economics and Outcomes Research Ltd, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Tarp+JM%22">Tarp JM</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Lincoff+AM%22">Lincoff AM</searchLink>; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228611864%22">Advances in therapy</searchLink> [Adv Ther] 2025 May; Vol. 42 (5), pp. 2513-2525. <i>Date of Electronic Publication: </i>2025 Mar 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Health+Communications+Inc%22">Health Communications Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8611864 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1865-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220741238X%22">0741238X </searchLink><i>NLM ISO Abbreviation: </i>Adv Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40156748
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12325-025-03176-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2513
    Titles:
      – TitleFull: The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lübker C
      – PersonEntity:
          Name:
            NameFull: Bhavsar J
      – PersonEntity:
          Name:
            NameFull: Duque do Vale R
      – PersonEntity:
          Name:
            NameFull: Emerson SS
      – PersonEntity:
          Name:
            NameFull: Nørtoft E
      – PersonEntity:
          Name:
            NameFull: Plutzky J
      – PersonEntity:
          Name:
            NameFull: Roberts G
      – PersonEntity:
          Name:
            NameFull: Tarp JM
      – PersonEntity:
          Name:
            NameFull: Lincoff AM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2025 May
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1865-8652
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Advances in therapy
              Type: main
ResultId 1